Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes.

This study investigated whether low-dose interleukin-2 (IL-2) therapy could attenuate arterial inflammation in patients with acute coronary syndromes (ACS). Researchers found that low-dose IL-2 treatment significantly reduced arterial inflammation, as evidenced by decreased inflammatory markers and improved plaque stability. These findings suggest that targeting immune pathways with low-dose IL-2 may offer a novel therapeutic strategy to mitigate cardiovascular risk and improve outcomes in ACS patients. Further research is warranted to confirm these benefits and establish optimal dosing and long-term safety.